Being recognized as a BCPP brings professional recognition and credibility as an expert in psychopharmacology and behavioral health matters.
In this month's peer-reviewed article, learn more about the illness affecting millions.
In this month's peer-reviewed article, learn more about the illness affecting millions.
In this month's peer-reviewed article, learn more about the illness affecting millions.
Jeffrey Bratberg, PharmD and Madi Hartling, a 2025 PharmD candidate, discuss the lack of pharmacists in medical shows and how pharmacists are typically portrayed negatively in media.
AACP offers a rebuttal to a Drug Topics opinion article.
With 2016 well underway, pharmacies of all sizes should review recent regulatory updates to ensure compliance with rules already in effect, and preparation for those to be implemented soon. Three, in particular, warrant a close look.
The primary challenges include disruption in medication supply and increased demand for essential medications due to heightened health concerns.
Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.
New developments in cancer treatment require medication experts-here's how you can become that expert.
Analysts have forecasted the market for NASH drugs could reach $20 billion by 2025.
An over-the-counter (OTC) progestin only pill (POP) could potentially reduce the overall number of unintended pregnancies in the United States.
Xadago has been approved as a supplementary medication for patients with Parkinson's disease who are having "off" episodes or whose disease is progressing.
The FDA has approved ocrelizumab for treating relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.
A high performing Pharmacy Services Administrative Organization (PSAO) actualizes its value proposition to its participating pharmacies by entering into viable strategic partnerships that add value to an independent pharmacy’s workflow processes.
FDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone
Delafloxacin (Baxdela) for treatment of acute bacterial skin and skin structure infections including cellulitis, wound infection, major cutaneous abscess, and burn infection.
Entresto® is a newly approved combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB) for patients who have chronic heart failure NYHA Class II-IV and reduced ejection fraction.
A drug underdevelopment may provide another pathway to lowering LDL levels.
A community hospital study found that a procedural change could save some big bucks.
A community hospital study found that a procedural change could save some big bucks.